Characterizing Cannabidiol Use in a Breast Cancer Population.

Abstract

Introduction: Cannabidiol (CBD) is a phytocannabinoid found in the plant Cannabis sativa and is thought to have broad potential therapeutic value. Little is reported on CBD use in patients with breast cancer (BC). This survey study aimed to characterize CBD use patterns and reported benefits among patients with BC, while also identifying barriers and limitations to its use.

Patients and methods: Individuals seen at the University of Michigan Rogel Cancer Center for a diagnosis of BC accessed the anonymous online survey characterizing current and former CBD use via flyer posted in clinic. Survey questions were adapted from a previously published questionnaire conducted in patients with chronic pain conditions. The survey was accessed between September 2020 and February 2024.

Results: Of 141 evaluable surveys, 68 patients (48.2%) reported prior or current CBD use. The most common reasons for current CBD use were management of pain (75.6%), anxiety (61.0%), and insomnia (58.5%). The biggest median self-reported improvement with use of CBD was in insomnia followed by pain. Patients mainly stopped using CBD because it was ineffective (46.2%), although some stopped due to negative side effects (7.7%).

Conclusion: Almost half of patients in this survey study reported previous or current CBD use, with improvements in symptoms. As CBD use increases in the clinical setting, it is important for physicians to help navigate concerns related to its use. Additional research is needed to determine which patient-reported symptoms are most likely to be impacted by CBD.